Storys zum Thema Biotechnologie

R-Biopharm AG

2

R-Biopharm AG announces personnel changes in the Board of Directors and restructuring

eleva GmbH

Björn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development

Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...

R-Biopharm AG

Blood Donation Day at R-Biopharm: Employees Help Save Lives

biomindz Standortentwicklungsgesellschaft Mainz GmbH i.G.

Newly established company to promote Mainz as hub for life science and biotechnology now operational and supporting the city of Mainz

CO.DON GmbH

CO.DON finally saved - investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg

Leipzig / Teltow (ots) - CO.DON continues business operations as a GmbH (limited liability company) With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a ...

R-Biopharm AG

Flu tests from R-Biopharm also detect new virus variants

RHEACELL GmbH und Co. KG

Stem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research

R-Biopharm AG

R-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories

LEUKOCARE AG

Leukocare announces new management structure to support global set-up and accelerate growth

Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the introduction of a new management structure, effective July 1st, 2022, designed to support the global organizational set-up and to further accelerate the company’s growth. The newly established Executive Board ...

R-Biopharm AG

R-Biopharm is IVDR certified

R-Biopharm AG

2

R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics

R-Biopharm AG

R-Biopharm announces test to detect monkeypox virus

Sysmex Inostics GmbH

University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients

Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...

The New Era Biotechnology Co., Ltd.

The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)

Almirall, S.A.

Almirall delivers solid nine months 2021 results and tightens its upgraded guidance

Barcelona, Spain (ots/PRNewswire) - - Strong Core business performance with growth in Core Net Sales EUR601.7 MM (+6.2% year-on-year) and Core EBITDA reaching EUR164.2 MM, (+20.3% year-on-year) driven by positive contribution from Growth Drivers and a strong EU dermatology performance - Key Growth Drivers underpinning increase in Core Net Sales. Strong performance from ...

LEUKOCARE AG

Dr. Dirk Winnemöller joins Leukocare as Vice President Commercial

Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced that Dr. Dirk Winnemöller took up the newly established role as Vice President Commercial at Leukocare. Dirk joins the Company from Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany, where he served as Global Vice ...

Almirall, S.A.

Almirall S.A.: Experts highlight the need to focus on psoriasis patients' wellbeing in clinical practice

Barcelona, Spain (ots/PRNewswire) - - Psoriasis affects the overall emotional wellbeing of 88% of patients[1], and at least 20% of psoriasis patients have considered suicide[2] - Currently used endpoints in psoriasis do not capture the full impact of this skin condition on patients' lives, and almost 50% of them ...

eleva GmbH

Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H

Freiburg (ots) - Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-art, 500 l single-use reactors from Sartorius Stedim Systems. The scale-up will enable Eleva to enter ...

Almirall, S.A.

Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials

Barcelona (ots/PRNewswire) - - Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis Lebrikizumab led to significant improvements with ...

Sysmex Inostics GmbH

Sysmex Inostics presents data at ASCO

Baltimore, MD (ots) - Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial. Sysmex Inostics, Inc., a global leader in the liquid biopsy revolution for oncology, is presenting the poster ...

eleva GmbH

Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member

Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to ...

EvoBiotiX

EvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)

Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...

BrainRepair UG

Regulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Plan

Versameb AG

Versameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials

Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...